The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 May 2026•

1 min read

Alvotech Reaffirms 2026 Guidance Despite Q1 Revenue Dip from Production Slowdown

Key Facts

1Alvotech reported Q1 2026 revenue of $105.9 million, impacted by production slowdowns due to facility improvements.

2The company reaffirmed its full-year 2026 revenue guidance of $650–700 million.

Alvotech reported Q1 2026 revenue of $105.9 million, a figure impacted by temporary production slowdowns linked to facility improvement projects. Despite the quarterly dip, the company reaffirmed its aggressive full-year 2026 revenue guidance, maintaining a target range of $650 million to $700 million. To mitigate future supply chain risks, Alvotech has entered into a strategic manufacturing agreement with FUJIFILM Biotechnologies. This partnership establishes a second U.S.-based commercial supply source, aimed at ensuring long-term operational stability. While the Q1 EBITDA and revenue figures showed year-over-year declines, the management's commitment to annual targets suggests confidence in a recovery during the latter half of the year. Investors are now focusing on the company's ability to scale production following these facility upgrades.